Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis - Xu, Cheng; Chen, Yu-Pei; Du, Xiao-Jing; Liu, Jin-Qi; Huang, Cheng-Long; Chen, Lei; Zhou, Guan-Qun; Li, Wen-Fei; Mao, Yan-Ping; Hsu, Chiun; Liu, Qing; Lin, Ai-Hua; et al. (BMJ. British medical journal (Clinical research ed.), 2018)
Keywords: Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Arthralgia; Cancer therapies; Chemotherapy; Clinical trials; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytotoxicity; Drug development; Drug dosages; Drug-Related Side Effects and Adverse Reactions - etiology; Evidence-based medicine; Humans; Hypothyroidism; Immune checkpoint inhibitors; Immunosuppressive agents; Immunotherapy; Ipilimumab - adverse effects; Ipilimumab - therapeutic use; Lung cancer; Lymphocytes; Medical prognosis; Medical research; Melanoma; Meta-analysis; Metastasis; Monoclonal antibodies; Nausea; Neoplasms - drug therapy; Neoplasms - immunology; Nivolumab - adverse effects; Nivolumab - therapeutic use; Pembrolizumab; Pharmaceutical industry; Pneumonitis; Prospero protein; Randomized Controlled Trials as Topic; Sensitivity analysis; Systematic review; Targeted cancer therapy; Toxicity; Vomiting